UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): ~~November~~April 2730, ~~2007~~2008

Lev Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

COMMISSION FILE NUMBER: 000-32947

DELAWARE	88-0211496
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

675 Third Avenue, Suite 2200

New York, NY 10017

(Address and zip code of principal executive offices)

(212) 682-3096

(Registrant's telephone number, including area code

_____________________________________________________

(Former name or former address, if changed since last report.)

CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1Item 7.01 Regulation FD Disclosure.

In connection with Lev Pharmaceuticals, Inc.’s upcoming panel meeting before the Blood Products Advisory Committee for the U.S. Food and Drug Administration, on April 30, 2008, the FDA posted briefing materials submitted by the Company. Attached as exhibit 99.1 to this Current Report on Form 8-K is a copy of the briefing materials submitted by the Company. The information in this Item 7.01 3and in exhibit 99.021 ~~Unregistered~~shall ~~Sales~~not be deemed to be “filed” for purposes of ~~Equity~~Section 18 of the Exchange Act or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. Furthermore, the furnishing of the information included in this Item 7.01 is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

The ~~information~~ materials ~~required~~included in exhibit 99.1 to bethis Current Report on Form 8-K contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in ~~this~~our ~~Item~~forward-looking 3statements and you should not place undue reliance on our forward-looking statements.02 ~~concerning~~Actual results or events could differ materially from the ~~grant~~plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to new information arising out of clinical ~~stock~~ trial ~~options~~results, the risk that the safety and/or efficacy results of existing clinical trials for Cinryze™ will not support approval for a biologics license, the risk that the FDA may require us to Mrconduct additional clinical trials for Cinryze™, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, our heavy dependence on the success of CinryzeTM, our dependence on our suppliers, our dependence on third parties to manufacture CinryzeTM, obtaining regulatory approval to market CinryzeTM, market acceptance of CinryzeTM, maintaining the orphan drug status associated with CinryzeTM, the risks associated with dependence upon key personnel, and our ability to obtain additional funding to support our business activities. ~~Dachowitz~~These isand ~~incorporated~~other ~~herein~~risks are described byin ~~reference~~greater ~~from~~detail ~~Item~~in the “Risk Factors” section of our filings with 5 the SEC.02 We do not assume any obligation to update any forward-looking statements.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Director and Related Compensation Matters

On November 27, 2007, the Board of Directors of the Lev Pharmaceuticals, Inc. (the “Registrant”) expanded the size of the Board to six persons and elected Mr. Henry M. Dachowitz as a director. In addition, the Board appointed Mr. Dachowitz to serve on the Audit Committee of the Board of Directors and as the Registrant’s Audit Committee Financial Expert. Mr. Dachowitz will serve for a term expiring at the Registrant’s next annual meeting of stockholders and until a successor is elected and qualified. There is no agreement or understanding between Mr. Dachowitz and any other person pursuant to which Mr. Dachowitz was appointed to the Board. Mr. Dachowitz is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-B. On November 28, 2007, the Registrant published a press release announcing Mr. Dachowitz’s election, which press release is annexed as Exhibit 99.1 to this Current Report.

Mr. Dachowitz formerly served as Treasurer of Nassau County, NY and is currently self-employed as a financial and business management advisor. From January 2002 to January 2006, Mr. Dachowitz served as Treasurer of Nassau County, NY where he also chaired the Nassau County Deferred Compensation Board ($500MM in assets). Prior to his appointment as Treasurer, Mr. Dachowitz was a tax arbitrage consultant with Twenty-First Securities and later with his own firm, Abacus Business Consultants. Mr. Dachowitz was also an auditor with Coopers & Lybrand, a management consultant with Touche Ross, a Divisional Controller with Bankers Trust, a research analyst with Sanford C. Bernstein & Company, and Chief Financial Officer of three start-up companies, including IGI Biotechnology, Inc. and Pharmos Corporation. Mr. Dachowitz presently serves as the Chief Financial Officer of two privately-held corporations, Biophore, Inc. and Espiga Records & Music. Mr. Dachowitz received his Bachelor of Science Degree from Brooklyn College and his Masters in Business Administration from Harvard Business School. A Certified Public Accountant, Mr. Dachowitz was a member of the Student Advisory Committee of the Institute of Politics at the Kennedy School of Government at Harvard University, and taught Accounting at Harvard College. Mr. Dachowitz served as an Editorial Advisor of the Journal of Accountancy from 1989 to 1999. Mr. Dachowitz is 51 years old.

In connection with his election, Mr. Dachowitz was granted options to purchase 100,000 shares of the Registrant’s Common Stock. The option award vests in equal installments over a four year period, with the first installment vesting on the one-year anniversary of the grant date of such options; is exercisable for a period of ten years at a per share exercise price equal to the market price of the Registrant’s Common Stock on the date of grant; and is entitled to immediately vest and remain exercisable in the event of a change in control of the company.

Further, on November 27, 2007, the Board adopted the following cash compensation policy for all non-executive directors to be effective as of January 1, 2007: (a) each non-executive director shall receive an annual fee for service as a non-executive director of $25,000; (b) each non-executive director that serves on the Registrant’s Audit or Compensation Committee shall receive an annual fee for service on such committees of $25,000, in addition to the annual fee for service on the Board; (c) the Chairman of the Audit Committee shall receive an annual fee for serving in such capacity of $25,000, in addition to other compensation to which such director receives for service on the Audit Committee; (d) the Registrant’s designated Audit Committee Financial Expert shall receive an annual fee for serving in such capacity of $25,000, in addition to other compensation to which such director receives for service on the Audit Committee; and (e) non-executive directors shall be entitled to have expenses incurred in attending meetings reimbursed.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 27, 2007, the Board approved an amendment to the Registrant’s Bylaws. The Bylaw amendment amends Article VII of the Bylaws by adding new Section 7.5 to authorize the Registrant to issue shares of stock without certificates in accordance with the Delaware General Corporation Law. The amendment to the Bylaws is effective immediately. The text of new Section 7.5 is attached to this Report as Exhibit 3.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(dc) ~~The following exhibits are filed or furnished herewith~~Exhibits.

~~Exhibit~~The following ~~No.~~exhibits ~~Description~~are offiled ~~Document~~or furnished herewith:

3.1 Amendment to Bylaws effective November 27, 2007

Exhibit No.		Description of Document

99.1		Briefing Materials Submitted by Lev Pharmaceuticals, Inc.

99.1 Press Release dated November 28, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	LEV PHARMACEUTICALS, INC.
	By:	/s/ Joshua D. Schein
		Name: Joshua D. Schein
		Title: Chief Executive Officer
		Date: December 3, 2007

		LEV PHARMACEUTICALS, INC.


		By: /s/ Joshua D. Schein, Ph. D.
		Name: Joshua D. Schein, Ph.D.
		Title: Chief Executive Officer
		Date: April 30, 2008

Exhibit Index

Exhibit No. Description of Document

Exhibit No.		Description of Document

99.1		Briefing Materials Submitted by Lev Pharmaceuticals, Inc.

3~~.1 Amendment to Bylaws effective November 27, 2007~~

99.1 Press Release dated November 28, 2007

Filing Compare · Lev Pharmaceuticals Inc